Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 19-65 years~* American Society of Anesthesiologists physical status (ASA PS) 1-2~* Patients scheduled for elective colonoscopy under Monitored Anesthesia Care in a University Hospital~* Patients who signed on written informed consent.~Exclusion Criteria:~* The exclusion criteria are refusal or inability to provide written informed consent~* Age \< 18 years~* Pregnancy~* Previous large bowel surgery~* Psychiatric disorders~* History of addiction to opiates and / or sedatives, and previous adverse reaction to any drug used in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: EXPERIMENTAL): remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
- midazolam and meperidine (Type: ACTIVE_COMPARATOR): a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)

Based on this trial design, predict the completion outcome and termination type (if applicable).